Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-18
2008-09-16
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S364000
Reexamination Certificate
active
07425558
ABSTRACT:
Methods and compositions are provided for treating sexual dysfunction, e.g., sexual dysfunction associated with drug treatment, using 5-HT1Areceptor antagonists.
REFERENCES:
patent: 5532244 (1996-07-01), Wong et al.
patent: 5532250 (1996-07-01), Wong et al.
patent: 5532264 (1996-07-01), Wong et al.
patent: 5532268 (1996-07-01), Wong et al.
patent: 5538992 (1996-07-01), Wong et al.
patent: 5552429 (1996-09-01), Wong et al.
patent: 5756532 (1998-05-01), Stack et al.
patent: 5776969 (1998-07-01), James
patent: 6127357 (2000-10-01), Cliffe et al.
patent: 6169105 (2001-01-01), Wong et al.
patent: 6566112 (2003-05-01), Jones et al.
patent: 7026320 (2006-04-01), Childers et al.
patent: A-0512755 (1992-11-01), None
patent: 0 687 472 (1995-12-01), None
patent: 0 792 649 (1997-09-01), None
patent: WO-94/13643 (1994-06-01), None
patent: WO-94/13644 (1994-06-01), None
patent: WO-94/13661 (1994-06-01), None
patent: WO-94/13676 (1994-06-01), None
patent: WO-94/13677 (1994-06-01), None
patent: WO-95/33725 (1995-12-01), None
patent: WO-95/33743 (1995-12-01), None
patent: WO-97/03982 (1997-02-01), None
patent: WO-02/44142 (2002-06-01), None
patent: WO-2004/082686 (2004-09-01), None
Beresford et al. Expert Opin.Emerging Drugs, vol. 8(1),p. 103-122 (2003).
Wood et al. Expert Opin.Investig.Drugs, vol. 11(4), p. 457-467 (2002).
Jankovic Mount Sinai Journal of Medicine, vol. 73, p. 682-689 (2006).
Testa et al. BJU International, vol. 87, p. 256-264 (2001).
Borg, Psychopharmacology, vol. 185, pp. 389-394 (2006).
Volpicelli, Medications for Alcoholism Treatment, posted on the web on Mar. 21, 2002 at http://www.tgorski.com/Medication/medications—for—alcoholism—treatment.htm) , pp. 1-17.
Blackburn, Drug Discovery Today:Therapeutic Strategies, vol. 1, p. 35-41 (2004).
Jones, et al, Pharmacology Biochemistry and Behavior 71, p. 555-568 (2002).
Robichaud, et al., Annual Reports in Med. Chem., Nov. 20, 2000, 35.
Sukoff Rizzo, et al., Society for Neuroscience Abstract #559.4 (2005).
Van Steen, et al., J. Med. Chem. 37:2761-2773 (1994).
Alexandre et al., 2006, Early Life Blockage of 5-Hydroxytryptamine 1A Receptors Normalizes Sleep and Depression-Like Behavior in Adult Knock-Out Mice Lacking the Serotonin Transporter, J. of Neuroscience 26(20)5554-5564.
Artigas et al., 1996, Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists, Trends Neurosci. 19(9):378-383.
Azmitia, 2001, Neuronal instability: implications for Rett's syndrome, Brain & Development 23:S1-S10.
Berends et al., 2005, A Review of the Neuroprotective Properties of the 5-HT1AReceptor Agonist Repinotan HCI (BAY ×3702) in Ischemic Stroke, CNS Drug Reviews 11(4)379-402.
Blanchard et al., 1997, An Ethopharmacological Analysis of Selective Activation of 5-HT1AReceptors: The Mouse 5-HT1ASyndrome, Pharmacology Biochem. and Behavior 57(4) 897-908.
Boast et al., 1999, 5HT Antagonists Attenuate MK801-Impaired Radial Arm Maze Performance in Rats, Neurobiol. Learning Memory 71:259-271.
Cao et al., 1997, Influence of 5-HT1AReceptor Antagonism on Plus-Maze Behaviour in Mice, Pharmacology Biochem. and Behavior 58(2): 593-603.
Cao et al., 1998, Tolerance to acute anxiolysis but no withdrawal anxiogenesis in mice treated chronically with 5-HT1Areceptor antagonist, WAY 100635, Neuroscience and Biobehavioral Reviews 23:247-257.
Carli et al., 1995, (S)-WAY-100135, a 5-HT1Areceptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine, Eur. J. Pharmacol. 283:133-139.
Carli et al., 1997, The 5-HT1Areceptor agonist 8-OH-DPAT reduces rats' accuracy of attentional performance and enhances impulsive responding in a five-choise serial reaction time task: role of presynaptic 5-HT1Areceptors, Brain Res. 774:167-174.
Carli et al., 1999, WAY 100635, a 5-HT1Areceptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal administration of scopolamine or 7-chloro-kynurenic acid, Neuropharmacol. 38:1165-1173.
Carli et al., 2000, WAY 100635, a 5-HT1Areceptor antagonist, prevents the impairment of spatial learning caused by blockade of hippocampal NMDA receptors, Psychopharmacol. 149:259-268.
Cheeta et al., 2001, The dorsal raphe nucleus is a crucial structure mediating nicotine's anxiolytic effects and the development of tolerance and withdrawal responses, Psychopharmacology 155:78-85.
Collinson et al., 1997, On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635, Psychopharmacology (Berl). 132(1):35-43.
Cryan et al., 1999, Comparative effects of serotonergic agonists with varying efficacy at the 5-HT1Areceptor on core body temperature: modification by the selective 5-HT1Areceptor antagonist WAY 100635, J. Psychopharmacol. 13:278-283.
Dijk et al., 1995, NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurons; evidence for modulation by a 5-HT1Aantagonist, British J. of Pharmacology 115(1169-1174).
Duxon et al., 2000, Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT1Areceptor antagonist WAY100635, British J. of Pharmaco. 130:1713-1719.
Fletcher et al., 1996, Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1Areceptor antagonist, Behav. Brain Res. 73:337-353.
Gudelsky et al., 1986, Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat, Neuropharmacology 25(12)1307-1313.
Harder et al., 2000, The 5-HT1Aantagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys, Neuropharmacol. 39:547-552.
Hjorth et al., 1997, WAY 100653-induced Augmentation of the 5-HT-elevating Action of Citalopram: Relative Importance of the Dose of the 5-HT1AAuto)receptor Blocker Versus that of the 5-HT Reuptake Inhibitor, Neuropharmacology 36(4/5):461-465.
Hughes et al., 1991, Symptoms of Tobacco Withdrawal, Arch. Gen. Psychiatry 48:52-59.
Hutson et al, 1988, Evidence that the hyperphagic response to 8-OH-DPAT is mediated by 5-HT1Areceptors, Eur. J. of Pharmacology 150:361-366.
Joordens et al., 1998, The effects of 5-HT1Areceptor agonists, 5-HT1Areceptor antagonists and their interaction on the fear-potentiated startle response, Psychopharmacol. 139:383-390.
Jorgensen et al., 1999, Adrenocorticotropic Hormone Secretion in Rats Induced by Stimulation with Serotonergic Compounds, J. of Neuroendocrinology 11:283-290.
Kakizaki et al., 2001, Effects of WAY100635, a selective 5-HT1Areceptor antagonist on the micturition-reflex pathway in the rat, Am. J. Physiol. Regul. Integr. Comp. Physiol. 280(5):R1407-1413.
Kalkman et al., 1995, RU 24969-induced locomotion in rats is mediated by 5-HT1Areceptors, Naunyn Schmiedeberg's Arch. Pharmacol. 352:583-584.
Kenny et al., 2000, Anxiogenic effects of nicotine in the dorsal hippocampus are mediated by 5-HT1Aand not by muscarinic M1receptors, Neuropharmacology 39:300-307.
Kenny et al., 2001, Nicotine regulates 5-HT1Areceptor gene expression in the cerebral cortex and dorsal hippocampus, Eur. J. Neurosci. 13:1267-1271.
Killcross et al., 1997, WAY100635 and latent inhibition in the rat: selective effects at preexposure, Behav. Brain Res. 88(1):51-57.
Kishitake, 2005, Effects of 5-HT1A-Receptor Agonist, 8-OH-DPAT, and GABA8-Receptor Agonist, Baclofen, on Lordosis in Female Rats with Lesions in Either the Dorsal Raphe Nucleus or Septum, J. Pharmacol. Sci. 98:419-424.
Krebs-Thomson et al., 1996, The role of 5-HT1Areceptors in the locomotor-suppressant effects of LSD: WAY-100635 studies of 8-OH-DPAT, DOI and LSD in rats, Behav. Pharmacol. 7:551-559.
Lin et al., 2002, Melatonin potentiates 5-HT1Areceptor activation in rat hypothalamus and results in hypothermia, J. of Pineal Research 33:14-19.
Mcvary et al., 1997, Sexual dysfunction in the diabetic BB/WOR rat: a role of central neuropathy, Am. J. Physiol. Regul. Integr. Comp. Physiol. 272:R259-267.
Mendelson et al., 1994
Childers Wayne Everett
Kelly Michael
Rosenzweig-Lipson Sharon Joy
Schechter Lee Erwin
Sukoff Rizzo Stacey J.
Bernhardt Emily
Wilmer Cutler Pickering Hale and Dorr LLP
Wyeth
LandOfFree
Serotonergic agents for treating sexual dysfunction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Serotonergic agents for treating sexual dysfunction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serotonergic agents for treating sexual dysfunction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3986974